RxDoctor Payments Data

Venkata Rama Gopala Damera

Nephrology · Shawnee, OKNPI 1861646358

Payments from drug & device makers

$1,335in general payments, 2019–2025

Across 70 payments — averaging $19.08 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AstraZeneca$310
  • Travere Therapeutics, Inc.$197
  • Boehringer Ingelheim$187
  • ANI Pharmaceuticals, Inc.$143
  • OPKO Pharmaceuticals, LLC$67
  • Vifor Pharma, Inc.$61
  • plus $370 from 12 others

What the payments were for

  • Food & beverage$1,28496%
  • Education$524%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$1,335 in reported general payments places this provider in the 35th percentile of 106 nephrology providers in Oklahoma.

See all nephrology providers in Oklahoma

Medicare billing

Part B allowed, 2024
$289,440
Medicare patients
813
Services billed
3,112

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
FarxigaDapagliflozin Propanediol495$472,599
JardianceEmpagliflozin495$435,293
LokelmaSodium Zirconium Cyclosilicate85$65,204
VeltassaPatiromer Calcium Sorbitex51$60,233
RayaldeeCalcifediol47$48,447
OzempicSemaglutide40$45,824
VelphoroSucroferric Oxyhydroxide15$43,353
MyrbetriqMirabegron65$43,001
KerendiaFinerenone40$25,875
Lanthanum Carbonate19$13,090
Cinacalcet Hcl29$11,111
Sevelamer Carbonate98$11,063
DapagliflozinDapagliflozin Propanediol14$9,808
Potassium Citrate ErPotassium Citrate50$7,516
Allopurinol744$7,005

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AstraZenecaFarxiga, Lokelma$310$537,803580 claims
Boehringer IngelheimJardiance$187$435,293495 claims
OPKO Pharmaceuticals, LLCRayaldee$67$48,44747 claims
Novo NordiskOzempic$51$45,82440 claims
Fresenius USA Marketing, Inc.Velphoro$20$43,35315 claims
BayerKerendia$15$25,87540 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 35th percentile of 106 nephrology providers in Oklahoma.

Other nephrology in Shawnee

See the full list for Oklahoma

Where these figures come from

Is this you, or does something look wrong? →